Bassetti Matteo, Righi Elda, De Pascale Gennaro, De Gaudio Raffaele, Giarratano Antonino, Mazzei Tereesita, Morace Giulia, Petrosillo Nicola, Stefani Stefania, Antonelli Massimo
Crit Care. 2014 Jul 25;18(4):458. doi: 10.1186/s13054-014-0458-4.
Invasive aspergillosis has been mainly reported among immunocompromised patients during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in the ICU population have shown an increasing risk profile for aspergillosis. Associations with chronic obstructive pulmonary disease and corticosteroid therapy have been frequently documented in this cohort. Difficulties in achieving a timely diagnosis of aspergillosis in non-neutropenic patients is related to the non-specificity of symptoms and to lower yields with microbiological tests compared to neutropenic patients. Since high mortality rates are typical of invasive aspergillosis in critically ill patients, a high level of suspicion and prompt initiation of adequate antifungal treatment are mandatory. Epidemiology, risk factors, diagnostic algorithms, and different approaches in antifungal therapy for invasive aspergillosis in non-neutropenic patients are reviewed.
侵袭性曲霉病主要在长期中性粒细胞减少的免疫功能低下患者中报道。然而,最近重症监护病房(ICU)的非中性粒细胞减少患者发生曲霉病的风险呈上升趋势。在这一队列中,慢性阻塞性肺疾病和皮质类固醇治疗与之相关的情况屡有记载。与中性粒细胞减少患者相比,非中性粒细胞减少患者难以及时诊断曲霉病,这与症状的非特异性以及微生物检测的阳性率较低有关。由于重症患者侵袭性曲霉病的死亡率通常较高,因此必须保持高度怀疑并迅速开始适当的抗真菌治疗。本文综述了非中性粒细胞减少患者侵袭性曲霉病的流行病学、危险因素、诊断算法以及抗真菌治疗的不同方法。